OBJECTIVE: This study aimed to explore the ability of the serum marker S100B to predict the development and severity of postconcussion syndrome (PCS) at 3 months in children after mild traumatic brain injury (mTBI). METHODS: This is a retrospective analysis of a prospective observational study conducted in a pediatric emergency department (ED). Children were eligible for the study if they were between the ages 5 and 18 years, presented within 6 hours of injury, met the case definition of mTBI from American Congress of Rehabilitation Medicine, had a Glasgow Coma Scale score of greater than 13, consented to have blood drawn for S100B levels, and completed the 3-month telephone follow-up. At the follow-up, the Rivermead Postconcussion Questionnaire was conducted to determine the development and severity of PCS. RESULTS: A total of 76 children were included in this cohort. The children had a mean (SD) age of 14.0 (3.1) years, 60.5% were male, and 89.5% had a Glasgow Coma Scale of 15. Twenty-eight (36.8%) developed PCS. For the children who developed PCS, the mean (SD) S100B level was 0.092 (0.376) µg/L. For children who did not develop PCS (n = 48), the mean (SD) S100B level was 0.022 (0.031) µg/L. The analyses did not support an association between initial S100B levels measured in the ED and development of PCS or severity of PCS symptoms. CONCLUSIONS: In this small sample, S100B, measured immediately after injury in the ED, did not seem to predict those children with mTBI who will go on to develop PCS.
OBJECTIVE: This study aimed to explore the ability of the serum marker S100B to predict the development and severity of postconcussion syndrome (PCS) at 3 months in children after mild traumatic brain injury (mTBI). METHODS: This is a retrospective analysis of a prospective observational study conducted in a pediatric emergency department (ED). Children were eligible for the study if they were between the ages 5 and 18 years, presented within 6 hours of injury, met the case definition of mTBI from American Congress of Rehabilitation Medicine, had a Glasgow Coma Scale score of greater than 13, consented to have blood drawn for S100B levels, and completed the 3-month telephone follow-up. At the follow-up, the Rivermead Postconcussion Questionnaire was conducted to determine the development and severity of PCS. RESULTS: A total of 76 children were included in this cohort. The children had a mean (SD) age of 14.0 (3.1) years, 60.5% were male, and 89.5% had a Glasgow Coma Scale of 15. Twenty-eight (36.8%) developed PCS. For the children who developed PCS, the mean (SD) S100B level was 0.092 (0.376) µg/L. For children who did not develop PCS (n = 48), the mean (SD) S100B level was 0.022 (0.031) µg/L. The analyses did not support an association between initial S100B levels measured in the ED and development of PCS or severity of PCS symptoms. CONCLUSIONS: In this small sample, S100B, measured immediately after injury in the ED, did not seem to predict those children with mTBI who will go on to develop PCS.
Authors: T Ingebrigtsen; B Romner; S Marup-Jensen; M Dons; C Lundqvist; J Bellner; C Alling; S E Børgesen Journal: Brain Inj Date: 2000-12 Impact factor: 2.311
Authors: M Otto; S Holthusen; E Bahn; N Söhnchen; J Wiltfang; R Geese; A Fischer; C D Reimers Journal: Int J Sports Med Date: 2000-11 Impact factor: 3.118
Authors: Nathan Kuppermann; James F Holmes; Peter S Dayan; John D Hoyle; Shireen M Atabaki; Richard Holubkov; Frances M Nadel; David Monroe; Rachel M Stanley; Dominic A Borgialli; Mohamed K Badawy; Jeff E Schunk; Kimberly S Quayle; Prashant Mahajan; Richard Lichenstein; Kathleen A Lillis; Michael G Tunik; Elizabeth S Jacobs; James M Callahan; Marc H Gorelick; Todd F Glass; Lois K Lee; Michael C Bachman; Arthur Cooper; Elizabeth C Powell; Michael J Gerardi; Kraig A Melville; J Paul Muizelaar; David H Wisner; Sally Jo Zuspan; J Michael Dean; Sandra L Wootton-Gorges Journal: Lancet Date: 2009-09-14 Impact factor: 79.321
Authors: Clinton D Morgan; Scott L Zuckerman; Lauren E King; Susan E Beaird; Allen K Sills; Gary S Solomon Journal: Childs Nerv Syst Date: 2015-09-29 Impact factor: 1.475
Authors: Jeremiah J Johnson; Andrea C Loeffert; Jennifer Stokes; Robert P Olympia; Harry Bramley; Steven D Hicks Journal: JAMA Pediatr Date: 2018-01-01 Impact factor: 16.193
Authors: Zoe S Gan; Sherman C Stein; Randel Swanson; Shaobo Guan; Lizette Garcia; Devanshi Mehta; Douglas H Smith Journal: Front Neurol Date: 2019-04-26 Impact factor: 4.003